[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES8605295A1 - Procedimiento de depuracion de antigeno del tipo de la hepa-titis - Google Patents

Procedimiento de depuracion de antigeno del tipo de la hepa-titis

Info

Publication number
ES8605295A1
ES8605295A1 ES548174A ES548174A ES8605295A1 ES 8605295 A1 ES8605295 A1 ES 8605295A1 ES 548174 A ES548174 A ES 548174A ES 548174 A ES548174 A ES 548174A ES 8605295 A1 ES8605295 A1 ES 8605295A1
Authority
ES
Spain
Prior art keywords
hbsag
soln
carrier
esp
pref
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES548174A
Other languages
English (en)
Other versions
ES548174A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Publication of ES548174A0 publication Critical patent/ES548174A0/es
Publication of ES8605295A1 publication Critical patent/ES8605295A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROCEDIMIENTO DE DEPURACION DE ANTIGENO DEL TIPO DE LA HEPATITIS. COMPRENDE: A) LIOFILIZAR A LAS CELULAS ESCHERICHIA COLI, BACILLUS SUBTILIS O LEVADURA, PARA PRODUCIR UN EXTRACTO DE HBSAG CRUDO; B) AÑADIR SAL INORGANICA A UNA SOLUCION HBSAG CRUDO Y AJUSTAR LA CONCENTRACION DE SAL INORGANICA ENTRE 5 Y 25 P/V%; C) PONER EN CONTACTO A LA SOLUCION DE B) CON 5 A 25 P/V% DE UNA SAL INORGANICA, PARA ABSORBER EL HBSAG SOBRE EL VECTOR; D) LAVAR EL VEHICULO CON UNA SAL INORGANICA QUE TIENE UNA CONCENTRACION ENTRE 10 Y 125 P/V%, PARA ELIMINAR LAS PROTEINAS CONTAMINANTES NO ABSORBIDAS; Y E) ELUIR EL HBSAG DE C) CON UNA SOLUCION TAMPON DE FOSFATO QUE TIENE UN 10 V/V% DE ETANOL Y PH 6 A 8. EL VEHICULO FIJADOR QUE TIENE GRUPOS HIDROFOBOS Y ES ELIGE ENTRE CELULOSA, DEXTRANO, ALQUILO DE C 2 A 8, PROPILO Y AMIDA POLIACRILICA Y LA SAL INORGANICA SE ELIGE ENTRE SULFATOS, CLORUROS O FOSFATOS COMO ANIONES Y AMONIO POTASIO O SODIO COMO CATIONES.
ES548174A 1984-10-26 1985-10-24 Procedimiento de depuracion de antigeno del tipo de la hepa-titis Expired ES8605295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59224116A JPS61103895A (ja) 1984-10-26 1984-10-26 ＨＢｓＡｇの精製方法

Publications (2)

Publication Number Publication Date
ES548174A0 ES548174A0 (es) 1986-04-01
ES8605295A1 true ES8605295A1 (es) 1986-04-01

Family

ID=16808783

Family Applications (1)

Application Number Title Priority Date Filing Date
ES548174A Expired ES8605295A1 (es) 1984-10-26 1985-10-24 Procedimiento de depuracion de antigeno del tipo de la hepa-titis

Country Status (7)

Country Link
US (1) US4694074A (es)
EP (1) EP0179485B1 (es)
JP (1) JPS61103895A (es)
KR (1) KR890001069B1 (es)
CA (1) CA1256042A (es)
DE (1) DE3579100D1 (es)
ES (1) ES8605295A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
JP5999899B2 (ja) 2008-04-08 2016-09-28 バイオ−ラッド ラボラトリーズ インコーポレーティッド 抗体のクロマトグラフィー精製法
BR112014011229B1 (pt) 2011-11-11 2021-10-13 Variation Biotechnologies, Inc Partículas vírus-like (vlp), composição farmacêutica compreendendo a referida partícula, método de produção e uso da mesma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB883549A (en) * 1958-09-03 1961-11-29 Crookes Lab Ltd Improvements in and relating to the purification of antihaemophilic globulin
US3951937A (en) * 1973-12-20 1976-04-20 The Community Blood Council Of Greater New York, Inc. Large scale purification of hepatitis type B antigen using polyethylene glycol
US3976767A (en) * 1975-04-14 1976-08-24 The New York Blood Center Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues
IL49752A (en) * 1975-07-09 1979-07-25 Kabi Ab Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration
DE2602892A1 (de) * 1976-01-27 1977-07-28 Community Blood Council Konzentriertes hepatitis-b-oberflaechenantigen enthaltende masse und verfahren zu ihrer herstellung
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
JPS5790650A (en) * 1980-11-28 1982-06-05 Toshiba Corp Control device for copying machine
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
US4515714A (en) * 1983-03-09 1985-05-07 Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute Method for purification of hepatitis B virus surface antigen
EP0135435A3 (en) * 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants

Also Published As

Publication number Publication date
DE3579100D1 (de) 1990-09-13
EP0179485A2 (en) 1986-04-30
EP0179485B1 (en) 1990-08-08
KR890001069B1 (ko) 1989-04-22
US4694074A (en) 1987-09-15
JPH0548240B2 (es) 1993-07-20
JPS61103895A (ja) 1986-05-22
ES548174A0 (es) 1986-04-01
CA1256042A (en) 1989-06-20
KR860003337A (ko) 1986-05-23
EP0179485A3 (en) 1988-09-28

Similar Documents

Publication Publication Date Title
Lin et al. Cyclic 3′: 5′-nucleotide phosphodiesterase: purification, characterization, and active form of the protein activator from bovine brain
Ratner [48] Enzymatic synthesis of arginine (condensing and splitting enzymes)
ATE96167T1 (de) Verfahren zur kristallisation von enzymen.
GB1420504A (en) Process for purifying effluents
FR2348942B3 (es)
Komoda et al. Partial purification and some properties of human liver alkaline phosphatase
ES8605295A1 (es) Procedimiento de depuracion de antigeno del tipo de la hepa-titis
ATE19390T1 (de) Verfahren zur wiedergewinnung von insulin.
FI852625A0 (fi) Foerfarande foer bildande av dubbelstraengade nukleinsyramolekyler fraon enkelstraengade nukleinsyramolekyler.
FR2632524B1 (fr) Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
Kern et al. Glycyl-tRNA synthetase from baker's yeast. Interconversion between active and inactive forms of the enzyme
ATE125174T1 (de) Verfahren für die selektive flotation von metallerzen mit 2-mercaptothiazolderivaten.
IE850608L (en) Process for the recovery of ceftazidime
US4189350A (en) Process for purifying urokinase
ATE13691T1 (de) Verfahren zum durchfuehren einer enzymatischen reaktion.
GB1502046A (en) Processes for treating water
FR2445312A1 (fr) Procede de purification de l'insuline
EP0184556A3 (en) Process for the manufacture of concentrated aqueous solutions of amino triazine reactive dyes with a low salt content
ES2001427A6 (es) Procedimiento de preparacion de un nuevo complejo solido apropiado para obtener proteinas insolubilizadas, aislar yno determinar fosfatos organicos y catalizar sitesis peptidicas.
ATE187151T1 (de) Verfahren zur stabilizierung von metallen in asche
Silva et al. [20] Orotate phosphoribosyltransferase: Orotidylate decarboxylase (Erythrocyte)
GB1508922A (en) Method for obtaining urokinase
KR880004086A (ko) 정제 효소 및 정제 효소의 제조방법
ATE27466T1 (de) Verfahren zur selektiven aufloesung von blei.
Krystek et al. Interaction of a phosphorylated site of muscle phosphofructokinase with the activation of the enzyme by NH4+ and K+

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20010301